Dermatologists use depigmenting creams with various active ingre dients in the treatment of melasma and postinflammatory hyper pigmentation.
[1] Skin lightening or bleaching refers to the cosmetic practice of applying depigmenting agents not as treatment for hyperpigmentation but with the deliberate aim of achieving a lighter skin colour. It is a practice that is common in many places (e.g. India, Africa and America) with pigmented populations and a history of improved social status with lighter complexion. Adverse effects are associated with active ingredients (mercury, hydroquinone and potent steroids) in depigmenting creams and are illegal in cosmetics in many countries. Further illegal ingredients in Africa have been shown to be imported from Europe (in spite of a European Union ban). [2] Glutathione (GSH) was first discovered by Hopkins [3[ in 1921 in yeasts, and subsequently in other tissues.
[4] It is a tripeptide com posed of Lcysteine, glycine and glutamate that is synthesised intra cellularly. [5, 6] It is considered the main redox buffer in human cells owing to its large amount of reducing equivalents, [7] and is an impor tant enzyme cofactor that serves as a neuromodulator in the central nervous system. The tripeptide exists intracellularly either in an oxidised glutathione disulphide (GSSG) or reduced state (GSH), and maintaining an optimal GSH:GSSG ratio in the cell is critical for prevention of oxidative damage and for cell survival (Fig. 1) . [8] An imbalance in GSH and its use as a marker of oxidative stress is reported in many diseases including cancer, neurodegenerative disorders, cystic fibrosis, HIV, [9] diabetes mellitus, [10] anorexia nervosa [11] and autism [12, 13] and in lowbirthweight neonates. [14] Reports of systemic skin lightening with GSH have appeared with increasing frequency on social media, and clinics advertise it online in many countries (Africa, the USA, Canada, Mexico, etc.). Our objective was to conduct a literature search to identify all academic reports of GSH use for skin lightening and all clinical trials of GSH use for all indications in medicine.
Methods
Two MEDLINE searches for studies published up to September 2015 were conducted. The search terms for the first were 'glutathione AND skin lightening' , and for the second 'glutathione AND randomised controlled trial' . Inclusion criteria were any treatment report of GSH for skin lightening (or hyperpigmentation) and GSH for any randomised control trial (RCT) for the first and second searches, respectively. Abstracts were read independently by two authors to identify relevant articles.
Results
Nine articles were identified from the first MEDLINE search. Six publications mentioned GSH as part of reviews related to melanin (kojic acid in rats, [15] piceatannol inhibition of mushroom tyrosin ase, [16] oral zinc sulphate murine hair hypopigmentation, [17] hydro quin one occupational exposure [18] (and toxicity for skin lightening) [19] and natural ingredientcontaining treatments for hyperpigmen tation. [20] A seventh article was an extensive review of biochemical mechanisms of how GSH causes depigmentation in cell cultures and laboratory animals. [21] Five clinical reports (4 published since 2012) of the use of GSH for skin lightening were identified (2 from the MEDLINE search and 3 from references). The first, a pharmacokinetic study of GSH in seven participants, did not measure skin lightening or report sideeffects. [22] A case series of 15 patients from India treated with a GSH containing soap for melanosis of the face reported lightening (in 11/15 after 3 months) based on clinical photographs. However, no mention was made of how the conditions for photography were standardised or of follow up on stopping treatment. [23] A controlled trial from Thailand tested 250 mg GSH capsules twice daily in two groups each of 30 medical students over 4 weeks. They repor ted a decreased melanin index measured at six body sites (but statistically significant only at two sites, namely the right side of the face (p=0.021) and the sunexposed left forearm (p=0.036)). [24] Watanabe et al. [25] from Japan reported a significant reduction in the melanin index (mean (standard deviation), daily for 8 weeks. [26] None of the studies repor ted significant adverse effects or follow up beyond the study period (Table 1) .
Of the plethora of articles retrieved from the second MEDLINE search, we identi fied 28 systematic reviews of animal stud ies, [3941] GSHrelated genetic polymorphisms linked to various cancers (colo rectal can cer, [42] leukaemia, [43, 44] lung cancer, [45, 46] blad der can cer, [47] gastric cancer, [48, 49] prostate cancer,
[5053] adult brain tumours, [54] basal cell carcinoma [55] ) and linked to other disorders (autism, [12, 13] hyper tension, [56, 57] respiratory diseases, [58, 59] cataract, [60] myelo dysplastic syndrome, [61, 62] glioma [63] and male idio pathic infertility. [64] ) There were 9 RCTs identified from two systematic reviews of the use of GSH to reduce chemotherapy induced toxicity (6 cisplatin, 2 axaliplatin, 1 platinum); most suggested less toxicity in GSH groups. A systematic review of GSH as an adjuvant therapy in Parkinson's disease identified one controlled trial [65] showing doubtful benefit. It was noteworthy that most studies did not report adverse events of GSH, and any reported were mild (Table 1) .
Discussion
The idea of GSHinduced hypopigmenta tion may stem from early studies linking sulfhydralcontaining compounds to the inhi bition of melanogenesis or from early anecdotal observations in Parkin son's dis ease. Proposed mechanisms of its action include inactivation of the melano genic enzyme, tyrosinase, influen cing the switch from eumelanin to phaeo melanin. [66, 67] During melano genesis, tyrosinase is res ponsible for the con version of Ltyro sine to LDOPA and subse quently to dopa quinone, then the path way bifurcates to produce eumela nin or phaeomelanin. At a critical point in the melanogenic path way (asterisk, Fig. 1 ), thiols (cysteine and GSH) can react with Ldopaquinone to produce gluta thionyldopa, or act as a reser voir of Lcysteine by conjugating with Ldopa quinone to produce cysteinyl dopa. These two thioldopa substrates serve as a precursor to enhance the switch from eumelano genesis to phaeomelano genesis, resulting in lighter skin pigmentation. [68, 69] This effect of GSH on skin pigmentation was reported half a century ago, with black human skin shown to exhibit lower levels of GSH than white skin. [70] In addition, GSH can act to lighten the skin directly through the quenching of free radicals and peroxides that have been shown to induce tyrosinase activity. [71] However, more evi dence is needed to prove this unequivocally.
GSH therefore has the potential to light en human skin. However, the only relia ble safety data on GSH are of sporadic use dur ing chemo therapy cycles, for a few weeks at most. There are no data on adverse effects of chronic highdose GSH as used for skin lightening.
All chemotoxicity studies used injectable GSH. Reactive oxygen species are easily de com posed in aqueous solution; this may explain the novelty of drug delivery as lozenges, which may be more stable (although two participants complained about the taste). The oral route reduces potential adverse events associated with intravenous (IV) administration but is associated with low bioavailability. Effective topical GSH [25] may be useful for dermatologists treating hyperpigmentation, but it is worth noting that GSH as a thiol interacts with metalloid complexes that render it ineffective. Patients should be advised to avoid using GSH with overthecounter skin lightening creams that may contain mercury.
[1]
All identified published trials report mild or no sideeffects of GSH use. However, study duration was a maximum of 12 weeks. We identified one case series that reported intolerable adverse effects leading to discon tinuation of 5 mg oral GSH daily as adjuvant treatment for hepatocellular carcinoma (HCC). Seven of 8 patients died within 
Fig. 1. GSH and its effect on skin lightening. Reactive oxygen species (ROS) have a direct activation effect on tyrosinase. Reduced GSH neutralises ROS formation and thus indirectly inhibits tyrosinase. At the dopachrome step* of the melanogenic pathway, interaction of thiols such as reduced GSH and cysteine bind with dopaquinone to produce thioldopas and favour phaeomelanogenesis. GST catalyses binding of GSH and dopaquinone. (DOPA = dihydroxyphenylalanine; DHI = dihydroxyindole; DHICA = dihydroxyindole carboxylic acid.)
1 year. However, the very severe prognosis associated with HCC was a likely confounder. [72] The effect of longterm administration of high doses of GSH on cells or organ systems remains unclear. Further more, since GSH causes a switch from eumelanin to phaeomelanin, it may increase UV photosensitivity, DNA damage and skin cancers in previously protected populations. [73] Of major concern are Bogliun et al., [30] 1992 Italy Placebo controlled Prevent cisplatin toxicity in ovarian cancer 33 CDDP total dose 500 675 mg/m 2 ± GSH 2.5 g/m 2 IV over 15 min, 1 wk Less severe neurotoxicity after cotreatment with all methods Similar in both groups except oliguria greater in placebo group Smyth et al., [31] 
Conclusion
This brief review evaluates recent clinical studies on the use of GSH. Despite widespread use of IV GSH, no clinical report was identified. Large RCTs of longenough duration and followup are warranted for the safe treatment of pigmentary disorders. The psychosocial impact of systemic skin lightening is a Pandora's box best addressed by multidisciplinary teams including social scientists, psychologists and psychiatrists.
Source of funding. Funded by the South African Medical Research
Council. [36] 1996 Italy Cases (uncontrolled) Parkinson's disease 9 600 mg GSH IV twice daily, 30 d, 4 mo 42% decline in disability, therapeutic effect lasted 2 4 mo None reported
Hauser et al., [37] 2009 USA RCT, pilot trial (placebo) Safety and preliminary efficacy in Parkinson's disease 21 1 400 mg GSH IV or placebo 3 times a wk, 4 wk 3 mo Unified Parkinson's Disease Rating Scale (UPDRS) motor scores higher in GSH group v. placebo No adverse events due to GSH Mischley et al., [38] 2015 USA Safety and tolerability of intranasal GSH in Parkinson's disease 30 600 mg/d of intranasal GSH v. placebo (saline) in 3 divided daily doses 3 mo All groups met tolerability criteria No adverse events due to GSH NR = not reported; IM = intramuscular.
